Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion.

PURPOSE: To evaluate the safety and efficacy of intravitreal triamcinolone acetonide (IVTA) for ischemic macular edema associated with branch retinal vein occlusion (BRVO) and foveal ischemia. DESIGN: Prospective interventional case series. METHODS: setting: Clinical practice. study population: Eig...

Full description

Bibliographic Details
Main Authors: Chen, S, Sundaram, V, Lochhead, J, Patel, C
Format: Journal article
Language:English
Published: 2006
_version_ 1797057045364473856
author Chen, S
Sundaram, V
Lochhead, J
Patel, C
author_facet Chen, S
Sundaram, V
Lochhead, J
Patel, C
author_sort Chen, S
collection OXFORD
description PURPOSE: To evaluate the safety and efficacy of intravitreal triamcinolone acetonide (IVTA) for ischemic macular edema associated with branch retinal vein occlusion (BRVO) and foveal ischemia. DESIGN: Prospective interventional case series. METHODS: setting: Clinical practice. study population: Eighteen eyes of 18 patients with macular edema associated with BRVO and foveal ischemia. intervention: Four mg IVTA. main outcome measures: Visual acuity (VA), optical coherence tomography, macular thickness measurements, and treatment-related complications. RESULTS: The mean duration of BRVO before treatment was 14 months. All patients were followed for a minimum of nine months, and 12 patients completed 12 months follow-up. The mean logarithm of the minimum angle of resolution (logMAR) VA improved significantly from 0.81 +/- 0.36 at baseline to 0.65 +/- 0.30 at one month (P = .03) but did not vary significantly from baseline at three, six, nine, and 12 months. Macular thickness improved significantly in all eyes from a mean of 400 +/- 134 mum preinjection, to 228 +/- 58 mum at one month (P < .01) and 256 +/- 121 mum at three months (P < .01) but did not vary significantly from baseline at six, nine, and 12 months. Eight eyes developed posterior subcapsular cataract, intraocular pressure (IOP) exceeded 21 mm Hg in four eyes, and two eyes developed vitreomacular traction during follow-up. CONCLUSIONS: IVTA is effective in reducing ischemic macular edema associated with BRVO and foveal capillary nonperfusion. This reduction is often associated with a temporary improvement in VA. Raised IOP and development of posterior subcapsular cataract are disadvantages of this treatment.
first_indexed 2024-03-06T19:30:49Z
format Journal article
id oxford-uuid:1d6827a2-a7f2-455c-b0a3-bd186cd8966e
institution University of Oxford
language English
last_indexed 2024-03-06T19:30:49Z
publishDate 2006
record_format dspace
spelling oxford-uuid:1d6827a2-a7f2-455c-b0a3-bd186cd8966e2022-03-26T11:10:35ZIntravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:1d6827a2-a7f2-455c-b0a3-bd186cd8966eEnglishSymplectic Elements at Oxford2006Chen, SSundaram, VLochhead, JPatel, C PURPOSE: To evaluate the safety and efficacy of intravitreal triamcinolone acetonide (IVTA) for ischemic macular edema associated with branch retinal vein occlusion (BRVO) and foveal ischemia. DESIGN: Prospective interventional case series. METHODS: setting: Clinical practice. study population: Eighteen eyes of 18 patients with macular edema associated with BRVO and foveal ischemia. intervention: Four mg IVTA. main outcome measures: Visual acuity (VA), optical coherence tomography, macular thickness measurements, and treatment-related complications. RESULTS: The mean duration of BRVO before treatment was 14 months. All patients were followed for a minimum of nine months, and 12 patients completed 12 months follow-up. The mean logarithm of the minimum angle of resolution (logMAR) VA improved significantly from 0.81 +/- 0.36 at baseline to 0.65 +/- 0.30 at one month (P = .03) but did not vary significantly from baseline at three, six, nine, and 12 months. Macular thickness improved significantly in all eyes from a mean of 400 +/- 134 mum preinjection, to 228 +/- 58 mum at one month (P < .01) and 256 +/- 121 mum at three months (P < .01) but did not vary significantly from baseline at six, nine, and 12 months. Eight eyes developed posterior subcapsular cataract, intraocular pressure (IOP) exceeded 21 mm Hg in four eyes, and two eyes developed vitreomacular traction during follow-up. CONCLUSIONS: IVTA is effective in reducing ischemic macular edema associated with BRVO and foveal capillary nonperfusion. This reduction is often associated with a temporary improvement in VA. Raised IOP and development of posterior subcapsular cataract are disadvantages of this treatment.
spellingShingle Chen, S
Sundaram, V
Lochhead, J
Patel, C
Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion.
title Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion.
title_full Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion.
title_fullStr Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion.
title_full_unstemmed Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion.
title_short Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion.
title_sort intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion
work_keys_str_mv AT chens intravitrealtriamcinoloneforthetreatmentofischemicmacularedemaassociatedwithbranchretinalveinocclusion
AT sundaramv intravitrealtriamcinoloneforthetreatmentofischemicmacularedemaassociatedwithbranchretinalveinocclusion
AT lochheadj intravitrealtriamcinoloneforthetreatmentofischemicmacularedemaassociatedwithbranchretinalveinocclusion
AT patelc intravitrealtriamcinoloneforthetreatmentofischemicmacularedemaassociatedwithbranchretinalveinocclusion